Table 1.
Demographic and clinical characteristics for all patients and by amyloid group
| All (n = 111) | A- (n = 49) | A+ (n = 62) | P | |
|---|---|---|---|---|
| Number of women/men | 57/54 | 20/29 | 37/25 | 0.05 |
| Age in years | 65.0 (8.4) | 61.4 (8.9) | 67.8 (6.8) | < 0.01 |
| Years of education | 13.8 (3.6) | 14.2 (3.4) | 13.5 (3.7) | 0.34 |
| MMSE* | 25.7 (4.1) | 27.1 (3.0) | 24.6 (4.4) | < 0.01 |
| CDR-SOB* | 3.3 (2.4) | 2.6 (2.3) | 3.9 (2.3) | < 0.01 |
| APOE ε4*, n (%) | 63 (57.8) | 17 (35.4) | 46 (75.4) | < 0.01 |
| Clinical diagnosis | < 0.01 | |||
| Clinical non-AD | 48 (43.2) | 41 (83.7) | 7 (11.3) | |
| Alzheimer’s clinical syndrome | 63 (56.8) | 8 (16.3) | 55 (88.7) | |
| Stage, n (%) | < 0.01 | |||
| SCD | 11 (9.9) | 9 (18.4) | 2 (3.2) | |
| MCI | 42 (37.8) | 27 (55.1) | 15 (24.2) | |
| Dementia | 58 (52.3) | 13 (26.5) | 45 (72.6) | |
| CSF Aβ42 pg/ml | 777.3 (353.8) | 1110.6 (231.1) | 513.9 (154.8) | < 0.01 |
| CSF T-tau pg/ml | 500.2 (367.9) | 336.9 (167.5) | 629.2 (428.5) | < 0.01 |
| CSF P-tau pg/ml | 71.7 (39.9) | 55.7 (22.3) | 84.3 (46.0) | < 0.01 |
| CSF nanoplaques, median (Q1;Q3) | 15 (11.4; 21.6) | 13.2 (10.8; 17.4) | 18 (12; 24.6) | 0.02† |
Data are given as mean (standard deviation) and P values are for two-tailed t-tests (continous variables) or χ2-tests (categorical variables) comparing amyloid groups, unless otherwise indicated
Aβ amyloid-β, AD Alzheimer’s disease, APOE apolipoprotein E, CDR-SOB Clinical Dementia Rating Scale Sum of Boxes, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, n number of patients, P-tau phosphorylated tau, Q quartile, SCD subjective cognitive decline, T-tau total tau
*MMSE, n = 104; CDR-SOB, n = 108; APOE, n = 109, † P-value for Mann-Whitney U test